PHTS is granted an International Classification of Diseases (ICD) Code! - Click here for more information.
Tom joined the Foundation in 2019 as Director of Clinical Development. In Spring of 2021 he was also appointed Chief Executive of the Foundation, a new role reflecting the growth of activity since the Foundation was formed in 2017. In his new role as Chief Executive, Tom oversees all the activities of the Foundation.
Tom continues to lead the Clinical Development activities of the Foundation, partnering with academic investigators and industry collaborators in order to support the Foundation’s mission.
Tom has 25 years of drug development experience gained from both the big pharma and the biotech sector. He has an extensive background in exploratory drug development in a range of therapeutic areas with a focus on oncology and cancer immunotherapy. Before joining PTEN research, Tom built up the European team as a Director of Clinical Operations for a Boston based biopharmaceutical company with a focus on rare diseases.
Tom is a graduate of University of Durham and is a Chartered Scientist.
Ask me about: The activities of the Foundation and strategy including clinical development, investigator sponsored trials/clinical collaborations, patient data and natural history studies.